AI for Science Enters Deep Waters: Five Chinese Biotech Firms Secure New Funding and File IPO Prospectuses

The notable features of this round of financing are:The investor lineup is highly diversified.——Both national-level state-owned capital(China Reform Holdings, Beijing State-owned Capital Management), Local State-Owned Assets(Pudong Venture Capital, Shenzhen Nanshan Strategic Emerging Industry Investment)、Top-tier Market-oriented VCs(Gaorong Ventures, Yunqi Partners), there is also industrial capital(Cathay Biotech, COFCO Emerging Industries Fund). Behind the consensus among investors lies a clear signal that AI for Science in the field of synthetic biology is moving from “proof of concept” into the deep waters of industrial implementation.。

01 MoleculeMind: The “Infrastructure Definer” of AI Protein Design

Features & Highlights:

MoleculeMind was founded by Professor Xu Jinbo, a world-class scientist hailed as the “pioneer of AI protein folding.”Xu Jinbo is the inventor of RaptorX-Contact, the world’s first effective AI algorithm for protein structure prediction, and is leading his team in driving a paradigm shift in biomacromolecule R&D from “random trial-and-error” to “programmable bioengineering.”。

MoleculeMind’s core competitive barrier lies in its self-developed, AI-native bioengineering infrastructure—MoleculeOS (MOS) Operating System。MOS is built on the company’s self-developed NewOrigin (Darwin) multimodal protein foundation large model, deeply integrating AI with first-principles physics to establish an engineering flywheel of “AI-driven precise design – wet-lab small-sample validation – continuous model evolution.”. At the technical level, MoleculeMind's foundational model for structure prediction, MMFold, achieved a landslide lead over mainstream domestic and international models such as Google's AlphaFold 3 in the FoldBench benchmark.。

At the industrial validation level, MoleculeMind’s AI-powered de novo design platform for biologics, MMDesign, achieved a target hit rate of over 90% in tests against 12 real-world clinical targets, successfully tackling industry-recognized “hard nuts” such as GPCRs and TNFα.. In the field of biomanufacturing, its technology has been applied to scenarios such as industrial enzyme engineering and strain optimization.。

Financing Status, Objectives, and Development Strategy:

On June 17, 2026, MoleculeMind announced the completion of its Series A financing round,Total Funding AmountOver $100 million. This round of financing saw participation from investors including Lanqiao Capital, Pudong Venture Capital, COFCO Emerging Industries Fund, Oriental Fortune Capital, Fosun RZ Capital, Guofang Venture Capital, Sepax Technologies, Infinity Group, Caixin Capital, and Zhengding, among others. Existing shareholders such as Cathay Biotech and Xinhang Capital continued to increase their investments.. Previously, MoleculeMind had received investments from renowned institutions such as Sequoia China, Baidu BV, and Lenovo Capital.。

The financing will be used forExpand the team of interdisciplinary talent, enhance the foundational large AI model for proteins and the MoleculeOS platform, and accelerate the industrial deployment and commercialization of AI-driven protein technologies.. The company has established a diversified business model comprising platform licensing, joint R&D, and self-developed pipelines., we will continue to advance industrial applications in fields such as innovative drugs and biomanufacturing.。

02 BioGeometry: The Builder of AI-Native “Microscopic World Models”

Features and Highlights:

BioGeometry is an AI-native biotechnology company founded in 2022 by Dr. Tang Jian, a leading scientist in AI-driven drug discovery, with Turing Award laureate and “Godfather of Deep Learning” Yoshua Bengio serving as Chief Scientific Advisor.。

Unlike the industry’s mainstream “AI+” approach, which treats AI as a tool for localized efficiency gains, BioGeometry choosesReconstructing the R&D Paradigm of Life Sciences from the Ground Up。The Company Leverages Generative AI to Build the Life Sciences Sector"Microscopic World Model"—The self-developed GeoFlow large model precisely models the interactions of biomolecules such as proteins, DNA, and RNA at atomic-level accuracy, leveraging generative AI to create entirely novel molecules from scratch that have never existed in nature.。

Bio-Geometry has also deeply integrated its AI models with an automated laboratory platform, constructing“Design–Experiment–Learning” Autonomous Closed Loop, enabling life to evolve from “being understood” to “being designed”The company has established two foundational platforms: the GeoBiologics AI-powered macromolecular drug design platform and a high-throughput wet-lab validation platform for macromolecular drugs, thereby achieving a closed-loop integration of dry and wet experiments.。

Financing Status, Objectives, and Development Layout:

In June 2026, BioGeometry announced the completion ofHundreds of millions of RMBStrategic FinancingThis round of financing was jointly led by Fortune Capital, Xinglian Capital (Z Fund), Guoke Investment, and Shanghai Bio-medicine Fund / SIIC Capital, with Index AI Industry Innovation Fund and Gaorong Ventures participating as follow-on investors.

Financing willTo support the continuous iteration of GeoFlow, our proprietary microscopic life science model, and to fully accelerate the construction of the company’s high-throughput automated laboratory and the advancement of its diversified innovative drug pipeline.. BioGeo’s application scenarios span antibodies, vaccines, peptides, and enzyme engineering, and it can be widely used across the entire biomanufacturing sector, including biopharmaceuticals, food, chemical industry, medical aesthetics, and materials.

03 Dapubio: A Leading Chinese Enterprise in Droplet Microfluidics

Features and Highlights:

Dapu Bio, incubated at the Hong Kong University of Science and Technology and founded in 2018, isA Leading Enterprise in High-Throughput Droplet Microfluidics Technology in ChinaThe company focuses on applying droplet microfluidics technology to the fields of biopharmaceuticals and precision medicine, striving to become a comprehensive solution provider integrating the research, development, and production of microfluidic chips, instruments, and reagents.。

Dapu Bio’s core technical capabilities lie in:Construct tens of millions of microdroplet reaction units within minutes and complete the screening of tens of millions of samples in a single round of experiments., breaking through the bottleneck of traditional well plate technology in screening throughput. The company has built a complete high-throughput, automated, and intelligent solution centered on the two core areas of drug discovery and synthetic biology, and has developed and commercialized more than ten high-end scientific instruments along with their accompanying chips, reagents, and consumables.。

Dapu Bio has servedOver 200 worldwideLeading Biopharmaceutical Companies, Synthetic Biology Firms, CRO Service Providers, Universities, and Research Institutions. Among the top 30 pharmaceutical companies by market capitalization and leading CROs in China, there are alreadyOver 80%Establish Business Collaboration with Dapu Bio。

Financing Status, Objectives, and Development Strategy:

On June 15, 2026, Dapu Bio announced the completion ofSeries B+Over 120 million yuanFinancing. This round of financing saw three consecutive closings within six months, securing support from several leading investment institutions, including the Intellectual Property Fund of Shanghai Science and Technology Innovation Group, Shenzhen Nanshan Strategic Emerging Investment, Shanghai Pudong Venture Capital, and Guangzhou Haihui Investment.. To date, Dapu Bio has secured cumulative financing exceeding RMB 300 million.。

The financing willPrimarily used to further strengthen core technology R&D, accelerate product iteration of high-end life science tool platforms, and focus investment on building an internationalization system.. Targeting high-growth scenarios such as global drug discovery, synthetic biology, and AI-driven life sciences R&D, Dapu Bio will continue to promote the large-scale global adoption of its independently developed instruments, consumables, and solutions.In 2026, the company was selected as one of the first batch of key supported projects in the HSITP@GAS Global Acceleration Program at the Hong Kong-Shenzhen Innovation and Technology Park.

04 Green Kangcheng: A Rising Star in AI-Driven Synthetic Biology Manufacturing from the Tsinghua University Ecosystem

Features & Highlights:

Green Kangcheng was registered and established in July 2022, as aDerived from the translation of core technological achievements at Tsinghua UniversityNational High-Tech Enterprise. The company is positioned to faceField of Active Ingredients for General Health and Bio-based Materialsan innovative biomanufacturing enterprise dedicated to achieving green, independent production of key chemicals through synthetic biology technologies。

The core advantage of Green Kangcheng lies in itsInternationally Leading Synthetic Biology Technology Platform，Especially the original"Non-Natural Biosynthesis" Platform。The company integrates computational biology and AI-driven biological element design, large-scale genome editing, construction of non-natural metabolic pathways, and efficient industrial engineering scale-up capabilities. Leveraging a core library of over 10,000 enzymes and more than ten industrial microbial chassis, it has established a comprehensive core technology system covering the entire chain from technological R&D to industrialization.。

Currently, Green Kangcheng hasCompletion of the Commissioning of the First Industrial-Scale Demonstration Platform, with a rich product pipeline.

Green Kangcheng Factory (Kaixing Bio) Actual View

Financing Status, Objectives, and Development Strategy:

In June 2026, Green Kangcheng announced the completion ofTens of millions of yuanPre-A Round FinancingThis round of financing was jointly invested by the Beijing Green Energy and Low-Carbon Industry Investment Fund under Beijing State-owned Capital Operation and Management Group, as well as Beijing Future Star Science and Technology Venture Capital Center and Beijing Changjianfa Investment Management Center under Future Science City Group.. Prior to this round of financing, Green Kangcheng had secured nearly RMB 100 million in investments from renowned institutions including China Merchants Venture Capital, CAS Star, TusStar, Changjin Holdings, and Cenglin Capital.。

Financing willPrimarily used to accelerate process scale-up and capacity building for high-value product pipelines, advance international certification of core raw materials and global market expansion, and initiate preliminary engineering for the next-generation large-scale production line.

05 Baiyao Tech: Pioneer of AI Virtual Cells

Features and Highlights:

Baiyao Technology is aAI Virtual Cell (AIVC) Platform Company, the founding team leverages top-tier scientific research resources from the Institute of Zoology, Chinese Academy of Sciences, and the Beijing Institute for Stem Cell and Regenerative Medicine. Since 2023, the company has been developing a foundational large model for AI virtual cells, with the aim ofAchieving Precise Analysis and Prediction of Cellular Behavior and State Changes。

Baiyao Technology has independently developed a pre-trained large cell model incorporating prior knowledge, which digitally simulates the life activities of real cells to construct a foundational model capable of characterizing cellular behavior and fate evolution.Leveraging the global large-scale AI-ready public datasets accumulated by the founding team over four years, the company has simultaneously implemented its proprietary dataset technology to collect high-quality, time-continuous perturbation datasets tailored for AIVC model training.。

In terms of industrialization, Baiyao Technology has collaborated with domestic and international partners inModel Deployment, Joint R&D of Cell Therapy Pipelines, Early Target Discovery, and Precision Stratification of Clinical Samplesadvance implementation in such scenarios, and actively build a closed-loop industry chain of “model-data-scenario”。

Financing Status, Objectives, and Development Strategy:

On June 5, 2026, Baiyao Technology announced the completion ofTens of Millions of YuanNew Round of FinancingThis round of financing was led by Guoxin Venture Capital Fund, under China Reform Holdings Corporation Ltd., a national-level state-owned capital operation platform, with participation from Daotong Capital and Yunqi Capital. Existing shareholders FreeS Fund and Baidu Ventures also increased their investments.. Previously, Baiyao Technology had completed a tens-of-millions-yuan angel round of financing in October 2025, led by FreeS Fund.。

Financing willPrimarily dedicated to the research and development of next-generation virtual cell algorithm models, exclusive data collection, and accelerating industrial commercialization.. The company is positioned asEngaged in cell therapy, gene therapy, recombinant protein development, and related fields.providing AI-enabled customized R&D solutions for biopharmaceutical companies and research institutions,Strategic Layout for the Synergistic Development of Advanced Cell Therapy and “AIDD plus AIVC”。